Candel Therapeutics Inc (CADL)
$6.14
Performance
- $5.96$6.36$6.14
2.93%
Downside
Day's Volatility :6.29%
Upside
3.46%
- $0.66$14.30$6.14
89.25%
Downside
52 Weeks Volatility :95.38%
Upside
57.06%
Returns
| Period | Candel Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -14.13% | 0.0% |
6 Months | 301.31% | 0.0% |
1 Year | 422.55% | 0.0% |
3 Years | -38.35% | -22.3% |
Highlights
Market Capitalization | 197.0M |
Book Value | - $0.32 |
Earnings Per Share (EPS) | -1.7 |
Wall Street Target Price | 11.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -52.31% |
Return On Equity TTM | -480.68% |
Revenue TTM | 31.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -20.7M |
EBITDA | -34.7M |
Diluted Eps TTM | -1.7 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 79.15%
Technicals Summary
Sell
Neutral
Buy
Candel Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Candel Therapeutics Inc | 22.31% | 301.31% | 422.55% | -38.35% | -12.29% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Candel Therapeutics Inc | NA | NA | NA | 0.0 | -4.81 | -0.52 | NA | -0.32 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Candel Therapeutics Inc | Buy | $197.0M | -12.29% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Candel Therapeutics Inc
Increasing Revenue
Revenue is up for the last 3 quarters, 31.0K → 1.77M (in $), with an average increase of 49.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -8.22M → -22.23M (in $), with an average decrease of 170.5% per quarter
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 107.6%
Institutional Holdings
Northpond Ventures, LLC
6.03%BlackRock Inc
2.57%Vanguard Group Inc
2.55%Sands Capital Ventures, LLC
1.26%Geode Capital Management, LLC
0.45%Bridgeway Capital Management, LLC
0.25%
Company Information
also known as advantagene. inc., we are a massachusetts-based biotechnology company developing our proprietary immuno-oncology platforms for the treatment of solid tumors, including our gene mediated cytotoxic (gmci™) platform and our rqnestin34.5 platform. gmci™ is an "off-the-shelf" immunotherapy designed to generate a personalized, robust, and precise systemic response from the patient's own immune system against his or her cancer.
Organization | Candel Therapeutics Inc |
Employees | 42 |
CEO | Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$6.14
-2.69%
Keyarch Acquisition Corp
$6.14
-2.69%
Connexa Sports Technologies Inc
$6.14
-2.69%
Us Value Etf
$6.14
-2.69%
First Wave Biopharma Inc
$6.14
-2.69%
Global X Msci Next Emerging
$6.14
-2.69%
Fat Projects Acquisition Corp
$6.14
-2.69%
Capital Link Global Fintech
$6.14
-2.69%
Applied Uv Inc
$6.14
-2.69%